{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:58:42Z","timestamp":1790063922756,"version":"4.0.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2023R1A2C1004720"],"award-info":[{"award-number":["2023R1A2C1004720"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2021R1A6C101A442"],"award-info":[{"award-number":["2021R1A6C101A442"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12272-025-01567-9","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:41:20Z","timestamp":1758771680000},"page":"983-1000","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dual inhibitors of P-glycoprotein and breast cancer resistance protein for overcoming the blood\u2013brain barrier: in silico discovery and preclinical evaluation"],"prefix":"10.1007","volume":"48","author":[{"given":"Jiyeon","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukyeong","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa Jeong","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyerim","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wankyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8706-4810","authenticated-orcid":false,"given":"Hwa Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"26","key":"1567_CR1","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.2174\/138161211797440186","volume":"17","author":"S Agarwal","year":"2011","unstructured":"Agarwal S, Hartz AM, Elmquist WF, Bauer B (2011) Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm des 17(26):2793\u20132802. https:\/\/doi.org\/10.2174\/138161211797440186","journal-title":"Curr Pharm des"},{"key":"1567_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejpb.2022.02.017","volume":"173","author":"V Balzer","year":"2022","unstructured":"Balzer V, Poc P, Puris E, Martin S, Aliasgari M, Auriola S, Fricker G (2022) Re-evaluation of the hCMEC\/D3 based in vitro BBB model for ABC transporter studies. Eur J Pharm Biopharm 173:12\u201321. https:\/\/doi.org\/10.1016\/j.ejpb.2022.02.017","journal-title":"Eur J Pharm Biopharm"},{"issue":"14","key":"1567_CR3","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865\u20132872. https:\/\/doi.org\/10.1200\/JCO.2004.12.149","journal-title":"J Clin Oncol"},{"issue":"2","key":"1567_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/pbc.25785","volume":"63","author":"S Bartholomae","year":"2016","unstructured":"Bartholomae S, Gruhn B, Debatin KM, Zimmermann M, Creutzig U, Reinhardt D, Steinbach D (2016) Coexpression of multiple ABC-transporters is strongly associated with treatment response in childhood acute myeloid leukemia. Pediatr Blood Cancer 63(2):242\u2013247. https:\/\/doi.org\/10.1002\/pbc.25785","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"1567_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1023\/a:1012510513780","volume":"54","author":"A Boiardi","year":"2001","unstructured":"Boiardi A, Eoli M, Salmaggi A, Zappacosta B, Fariselli L, Milanesi I, Broggi G, Silvani A (2001) Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. J Neuro-Oncol 54(1):39\u201347. https:\/\/doi.org\/10.1023\/a:1012510513780","journal-title":"J Neuro-Oncol"},{"issue":"Suppl","key":"1567_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0014-4835(77)80008-0","volume":"25","author":"MW Brightman","year":"1977","unstructured":"Brightman MW (1977) Morphology of blood-brain interfaces. Exp Eye Res 25(Suppl):1\u201325. https:\/\/doi.org\/10.1016\/s0014-4835(77)80008-0","journal-title":"Exp Eye Res"},{"issue":"2","key":"1567_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.brainresrev.2010.05.003","volume":"64","author":"FL Cardoso","year":"2010","unstructured":"Cardoso FL, Brites D, Brito MA (2010) Looking at the blood\u2013brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev 64(2):328\u2013363. https:\/\/doi.org\/10.1016\/j.brainresrev.2010.05.003","journal-title":"Brain Res Rev"},{"issue":"1","key":"1567_CR8","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/neuonc\/now197","volume":"19","author":"MC Chamberlain","year":"2017","unstructured":"Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ (2017) Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro-Oncol 19(1):i1\u2013i24. https:\/\/doi.org\/10.1093\/neuonc\/now197","journal-title":"Neuro-Oncol"},{"issue":"1","key":"1567_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","volume":"370","author":"Z Chen","year":"2016","unstructured":"Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L, Li J (2016) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett 370(1):153\u2013164. https:\/\/doi.org\/10.1016\/j.canlet.2015.10.010","journal-title":"Cancer Lett"},{"issue":"9","key":"1567_CR10","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1158\/0008-5472.CAN-03-2033","volume":"64","author":"S Cisternino","year":"2004","unstructured":"Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann J-M (2004) Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64(9):3296\u20133301. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-2033","journal-title":"Cancer Res"},{"issue":"6","key":"1567_CR11","first-page":"825","volume":"91","author":"D Damiani","year":"2006","unstructured":"Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, Michelutti A, Cavallin M, Fanin R (2006) The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 91(6):825\u2013828","journal-title":"Haematologica"},{"issue":"5","key":"1567_CR12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.bcp.2008.11.001","volume":"77","author":"S Dauchy","year":"2009","unstructured":"Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, Romero IA, Scherrmann JM, De Waziers I, Decleves X (2009) Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC\/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 77(5):897\u2013909. https:\/\/doi.org\/10.1016\/j.bcp.2008.11.001","journal-title":"Biochem Pharmacol"},{"issue":"21","key":"1567_CR13","doi-asserted-by":"publisher","first-page":"6440","DOI":"10.1158\/1078-0432.CCR-07-1335","volume":"13","author":"NA de Vries","year":"2007","unstructured":"de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellingen O (2007) P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13(21):6440\u20136449. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1335","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1567_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/aps.2016.121","volume":"38","author":"L Deng","year":"2017","unstructured":"Deng L, Jiang L, Lin XH, Tseng KF, Liu Y, Zhang X, Dong RH, Lu ZG, Wang XJ (2017) The PI3K\/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia. Acta Pharmacol Sin 38(3):382\u2013391. https:\/\/doi.org\/10.1038\/aps.2016.121","journal-title":"Acta Pharmacol Sin"},{"issue":"26","key":"1567_CR15","doi-asserted-by":"publisher","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","volume":"95","author":"LA Doyle","year":"1998","unstructured":"Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95(26):15665\u201315670. https:\/\/doi.org\/10.1073\/pnas.95.26.15665","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"1567_CR16","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1021\/mp3003144","volume":"9","author":"S Durmus","year":"2012","unstructured":"Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH (2012) Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm 9(11):3236\u20133245. https:\/\/doi.org\/10.1021\/mp3003144","journal-title":"Mol Pharm"},{"issue":"6","key":"1567_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2020.129556","volume":"1864","author":"DE Durrant","year":"2020","unstructured":"Durrant DE, Das A, Dyer S, Kukreja RC (2020) A dual PI3 kinase\/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines. Biochim Biophys Acta (BBA) 1864(6):129556. https:\/\/doi.org\/10.1016\/j.bbagen.2020.129556","journal-title":"Biochim Biophys Acta (BBA)"},{"key":"1567_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2045-8118-10-33","volume":"10","author":"DE Eigenmann","year":"2013","unstructured":"Eigenmann DE, Xue G, Kim KS, Moses AV, Hamburger M, Oufir M (2013) Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC\/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood\u2013brain barrier model for drug permeability studies. Fluids Barriers CNS 10:1\u201317","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"1567_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11060-016-2253-3","volume":"130","author":"JA Ellis","year":"2016","unstructured":"Ellis JA, Cooke J, Singh-Moon RP, Wang M, Bruce JN, Emala CW, Bigio IJ, Joshi S (2016) Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas. J Neuro-Oncol 130(3):449\u2013454. https:\/\/doi.org\/10.1007\/s11060-016-2253-3","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"1567_CR20","first-page":"739","volume":"61","author":"C Erlichman","year":"2001","unstructured":"Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH (2001) The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 61(2):739\u2013748","journal-title":"Cancer Res"},{"issue":"6","key":"1567_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1023\/a:1012866803188","volume":"33","author":"MM Gottesman","year":"2001","unstructured":"Gottesman MM, Ambudkar SV (2001) Overview: ABC transporters and human disease. J Bioenerg Biomembr 33(6):453\u2013458. https:\/\/doi.org\/10.1023\/a:1012866803188","journal-title":"J Bioenerg Biomembr"},{"issue":"1","key":"1567_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF00163544","volume":"6","author":"RM Green","year":"1988","unstructured":"Green RM, Stewart DJ, Hugenholtz H, Richard MT, Thibault M, Montpetit V (1988) Human central nervous system and plasma pharmacology of mitoxantrone. J Neuro-Oncol 6(1):75\u201383. https:\/\/doi.org\/10.1007\/BF00163544","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"1567_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054181","volume":"8","author":"D He","year":"2013","unstructured":"He D, Zhao XQ, Chen XG, Fang Y, Singh S, Talele TT, Qiu HJ, Liang YJ, Wang XK, Zhang GQ, Chen ZS, Fu LW (2013) BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells. PLoS ONE 8(1):e54181. https:\/\/doi.org\/10.1371\/journal.pone.0054181","journal-title":"PLoS ONE"},{"issue":"5","key":"1567_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/0271678X16630991","volume":"36","author":"HC Helms","year":"2016","unstructured":"Helms HC, Abbott NJ, Burek M, Cecchelli R, Couraud P-O, Deli MA, F\u00f6rster C, Galla HJ, Romero IA, Shusta EV (2016) In vitro models of the blood\u2013brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use. J Cereb Blood Flow Metab 36(5):862\u2013890. https:\/\/doi.org\/10.1177\/0271678X16630991","journal-title":"J Cereb Blood Flow Metab"},{"key":"1567_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ijpharm.2019.05.074","volume":"566","author":"S Hinkel","year":"2019","unstructured":"Hinkel S, Mattern K, Dietzel A, Reichl S, M\u00fcller-Goymann C (2019) Parametric investigation of static and dynamic cell culture conditions and their impact on hCMEC\/D3 barrier properties. Int J Pharmaceut 566:434\u2013444. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.05.074","journal-title":"Int J Pharmaceut"},{"issue":"3","key":"1567_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1471-4159.2004.02537.x","volume":"90","author":"S Hori","year":"2004","unstructured":"Hori S, Ohtsuki S, Tachikawa M, Kimura N, Kondo T, Watanabe M, Nakashima E, Terasaki T (2004) Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J Neurochem 90(3):526\u2013536. https:\/\/doi.org\/10.1111\/j.1471-4159.2004.02537.x","journal-title":"J Neurochem"},{"issue":"5","key":"1567_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1023\/a:1018972102702","volume":"10","author":"J Hunter","year":"1993","unstructured":"Hunter J, Hirst BH, Simmons NL (1993) Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 10(5):743\u2013749. https:\/\/doi.org\/10.1023\/a:1018972102702","journal-title":"Pharm Res"},{"issue":"4","key":"1567_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad045","volume":"7","author":"S Johnston","year":"2023","unstructured":"Johnston S, Emde A, Barrios C, Srock S, Neven P, Martin M, Cameron D, Janni W, Gnant M (2023) Cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors: existing and emerging differences. JNCI Cancer Spectr 7(4):pkad045. https:\/\/doi.org\/10.1093\/jncics\/pkad045","journal-title":"JNCI Cancer Spectr"},{"issue":"20","key":"1567_CR29","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1093\/jnci\/92.20.1651","volume":"92","author":"JW Jonker","year":"2000","unstructured":"Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. JNCI-J Natl Cancer I 92(20):1651\u20131656. https:\/\/doi.org\/10.1093\/jnci\/92.20.1651","journal-title":"JNCI-J Natl Cancer I"},{"issue":"1","key":"1567_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta (BBA) 455(1):152\u2013162. https:\/\/doi.org\/10.1016\/0005-2736(76)90160-7","journal-title":"Biochim Biophys Acta (BBA)"},{"key":"1567_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","volume":"18","author":"RJ Kathawala","year":"2015","unstructured":"Kathawala RJ, Gupta P, Ashby CR Jr., Chen ZS (2015) The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Update 18:1\u201317. https:\/\/doi.org\/10.1016\/j.drup.2014.11.002","journal-title":"Drug Resist Update"},{"key":"1567_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.36295\/ASRO.2020.231550","volume":"23","author":"MT Kaur","year":"2020","unstructured":"Kaur MT, Bhandari DD, Kaur T (2020) A review on BCRP inhibitors: An upcoming strategy for cancer treatment. Ann Trop Med Public Health 23:231\u2013550. https:\/\/doi.org\/10.36295\/ASRO.2020.231550","journal-title":"Ann Trop Med Public Health"},{"issue":"3","key":"1567_CR33","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1124\/jpet.109.162321","volume":"333","author":"H Kodaira","year":"2010","unstructured":"Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp\/Abcb1) and breast cancer resistance protein (Bcrp\/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 333(3):788\u2013796. https:\/\/doi.org\/10.1124\/jpet.109.162321","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"1567_CR34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1021\/acs.jcim.2c01300","volume":"63","author":"Y Kwon","year":"2023","unstructured":"Kwon Y, Park S, Lee J, Kang J, Lee HJ, Kim W (2023) BEAR: a novel virtual screening method based on large-scale bioactivity data. J Chem Inf Model 63(5):1429\u20131437. https:\/\/doi.org\/10.1021\/acs.jcim.2c01300","journal-title":"J Chem Inf Model"},{"issue":"7","key":"1567_CR35","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-08-2253","volume":"15","author":"JS Lagas","year":"2009","unstructured":"Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, Schinkel AH (2009) Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res 15(7):2344\u20132351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2253","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1567_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/pharmaceutics13040559","volume":"13","author":"J Lee","year":"2021","unstructured":"Lee J, Kang J, Kwon NY, Sivaraman A, Naik R, Jin SY, Oh AR, Shin JH, Na Y, Lee K, Lee HJ (2021) Dual inhibition of P-gp and BCRP improves oral topotecan bioavailability in rodents. Pharmaceutics 13(4):559. https:\/\/doi.org\/10.3390\/pharmaceutics13040559","journal-title":"Pharmaceutics"},{"issue":"5","key":"1567_CR37","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/1078-0432.CCR-16-1276","volume":"23","author":"F Lin","year":"2017","unstructured":"Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil LC, Thota N, Sparidans RW, Beijnen JH, Wurdinger T, van Tellingen O (2017) PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models. Clin Cancer Res 23(5):1286\u20131298. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1276","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1567_CR38","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1242\/jcs.113.11.2011","volume":"113","author":"T Litman","year":"2000","unstructured":"Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113(11):2011\u20132021. https:\/\/doi.org\/10.1242\/jcs.113.11.2011","journal-title":"J Cell Sci"},{"issue":"9","key":"1567_CR39","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3324\/haematol.2010.031823","volume":"96","author":"C Marzac","year":"2011","unstructured":"Marzac C, Garrido E, Tang R, Fava F, Hirsch P, De Benedictis C, Corre E, Lapusan S, Lallemand J-Y, Marie J-P (2011) ATP binding cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients. Haematologica 96(9):1293. https:\/\/doi.org\/10.3324\/haematol.2010.031823","journal-title":"Haematologica"},{"issue":"1\u20132","key":"1567_CR40","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ijpharm.2012.05.028","volume":"434","author":"M Minocha","year":"2012","unstructured":"Minocha M, Khurana V, Qin B, Pal D, Mitra AK (2012a) Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp\/Abcb1) and breast cancer resistance protein (Bcrp1\/Abcg2) mediated efflux with m-TOR inhibitors. Int J of Pharmaceut 434(1\u20132):306\u2013314. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.05.028","journal-title":"Int J of Pharmaceut"},{"issue":"1\u20132","key":"1567_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijpharm.2012.05.038","volume":"436","author":"M Minocha","year":"2012","unstructured":"Minocha M, Khurana V, Qin B, Pal D, Mitra AK (2012b) Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. Int J Pharm 436(1\u20132):127\u2013134. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.05.038","journal-title":"Int J Pharm"},{"issue":"9","key":"1567_CR42","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S0090-9556(24)02969-6","volume":"32","author":"N Mizuno","year":"2004","unstructured":"Mizuno N, Suzuki M, Kusuhara H, Suzuki H, Takeuchi K, Niwa T, Jonker JW, Sugiyama Y (2004) Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1\/ABCG2) knockout mice. Drug Metab Dispos 32(9):898\u2013901. https:\/\/doi.org\/10.1016\/S0090-9556(24)02969-6","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1567_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7(2):27. https:\/\/doi.org\/10.4103\/0976-0105.177703","journal-title":"J Basic Clin Pharm"},{"issue":"1","key":"1567_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cell.2009.04.030","volume":"138","author":"DX Nguyen","year":"2009","unstructured":"Nguyen DX, Chiang AC, Zhang XH-F, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massagu\u00e9 J (2009) WNT\/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138(1):51\u201362. https:\/\/doi.org\/10.1016\/j.cell.2009.04.030","journal-title":"Cell"},{"issue":"1","key":"1567_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1021\/mp3004308","volume":"10","author":"S Ohtsuki","year":"2013","unstructured":"Ohtsuki S, Ikeda C, Uchida Y, Sakamoto Y, Miller F, Glacial F, Decleves X, Scherrmann J-M, Couraud P-O, Kubo Y (2013) Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC\/D3 as a human blood\u2013brain barrier model. Mol Pharmaceut 10(1):289\u2013296. https:\/\/doi.org\/10.1021\/mp3004308","journal-title":"Mol Pharmaceut"},{"issue":"13","key":"1567_CR46","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.2174\/092986712800167392","volume":"19","author":"A Palmeira","year":"2012","unstructured":"Palmeira A, Sousa E, Vasconcelos MH, Pinto MM (2012) Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 19(13):1946\u20132025. https:\/\/doi.org\/10.2174\/092986712800167392","journal-title":"Curr Med Chem"},{"issue":"6","key":"1567_CR47","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0305-7372(03)00105-1","volume":"29","author":"RA Patchell","year":"2003","unstructured":"Patchell RA (2003) The management of brain metastases. Cancer Treat Rev 29(6):533\u2013540. https:\/\/doi.org\/10.1016\/S0305-7372(03)00105-1","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1567_CR48","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/j.1471-4159.2008.05730.x","volume":"107","author":"B Poller","year":"2008","unstructured":"Poller B, Gutmann H, Kr\u00e4henb\u00fchl S, Weksler B, Romero I, Couraud PO, Tuffin G, Drewe J, Huwyler J (2008) The human brain endothelial cell line hCMEC\/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem 107(5):1358\u20131368. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05730.x","journal-title":"J Neurochem"},{"key":"1567_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109289","volume":"118","author":"A Sampson","year":"2019","unstructured":"Sampson A, Peterson BG, Tan KW, Iram SH (2019) Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents. Biomed Pharmacother 118:109289. https:\/\/doi.org\/10.1016\/j.biopha.2019.109289","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"1567_CR50","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1002\/cncr.10541","volume":"94","author":"LJ Schouten","year":"2002","unstructured":"Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698\u20132705. https:\/\/doi.org\/10.1002\/cncr.10541","journal-title":"Cancer"},{"issue":"13","key":"1567_CR51","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"P Skehan","year":"1990","unstructured":"Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. JNCI-J Natl Cancer I 82(13):1107\u20131112. https:\/\/doi.org\/10.1093\/jnci\/82.13.1107","journal-title":"JNCI-J Natl Cancer I"},{"issue":"4","key":"1567_CR52","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/hep.510270422","volume":"27","author":"JW Smit","year":"1998","unstructured":"Smit JW, Schinkel AH, M\u00fcller M, Weert B, Meijer DK (1998) Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology 27(4):1056\u20131063","journal-title":"Hepatology"},{"issue":"6","key":"1567_CR53","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/jnci\/93.6.436","volume":"93","author":"R Soni","year":"2001","unstructured":"Soni R, O\u2019Reilly T, Furet P, Muller L, Stephan C, Zumstein-Mecker S, Fretz H, Fabbro D, Chaudhuri B (2001) Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. JNCI-J Natl Cancer I 93(6):436\u2013446. https:\/\/doi.org\/10.1093\/jnci\/93.6.436","journal-title":"JNCI-J Natl Cancer I"},{"issue":"5","key":"1567_CR54","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","volume":"94","author":"A Sparreboom","year":"1997","unstructured":"Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94(5):2031\u20132035. https:\/\/doi.org\/10.1073\/pnas.94.5.2031","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3 Pt 2","key":"1567_CR55","doi-asserted-by":"publisher","first-page":"H484","DOI":"10.1152\/ajpheart.1984.247.3.H484","volume":"247","author":"Y Takasato","year":"1984","unstructured":"Takasato Y, Rapoport SI, Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247(3 Pt 2):H484-493. https:\/\/doi.org\/10.1152\/ajpheart.1984.247.3.H484","journal-title":"Am J Physiol"},{"issue":"28","key":"1567_CR56","doi-asserted-by":"publisher","first-page":"20383","DOI":"10.1016\/S0021-9258(19)88713-6","volume":"267","author":"T Tatsuta","year":"1992","unstructured":"Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T (1992) Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 267(28):20383\u201320391. https:\/\/doi.org\/10.1016\/S0021-9258(19)88713-6","journal-title":"J Biol Chem"},{"issue":"6","key":"1567_CR57","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/0006-2952(93)90677-o","volume":"46","author":"A Tsuji","year":"1993","unstructured":"Tsuji A, Tamai I, Sakata A, Tenda Y, Terasaki T (1993) Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem Pharmacol 46(6):1096\u20131099. https:\/\/doi.org\/10.1016\/0006-2952(93)90677-o","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"1567_CR58","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1043-6618(03)00158-0","volume":"48","author":"MV Varma","year":"2003","unstructured":"Varma MV, Ashokraj Y, Dey CS, Panchagnula R (2003) P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48(4):347\u2013359. https:\/\/doi.org\/10.1016\/S1043-6618(03)00158-0","journal-title":"Pharmacol Res"},{"issue":"11","key":"1567_CR59","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.nucmedbio.2015.07.004","volume":"42","author":"ML Vlaming","year":"2015","unstructured":"Vlaming ML, L\u00e4ppchen T, Jansen HT, Kivits S, van Driel A, van de Steeg E, van der Hoorn JW, Sio CF, Steinbach OC, DeGroot J (2015) PET-CT imaging with [18F]-gefitinib to measure Abcb1a\/1b (P-gp) and Abcg2 (Bcrp1) mediated drug\u2013drug interactions at the murine blood\u2013brain barrier. Nucl Med Biol 42(11):833\u2013841. https:\/\/doi.org\/10.1016\/j.nucmedbio.2015.07.004","journal-title":"Nucl Med Biol"},{"issue":"13","key":"1567_CR60","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1096\/fj.04-3458fje","volume":"19","author":"BB Weksler","year":"2005","unstructured":"Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO (2005) Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19(13):1872\u20131874. https:\/\/doi.org\/10.1096\/fj.04-3458fje","journal-title":"FASEB J"},{"key":"1567_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2045-8118-10-16","volume":"10","author":"B Weksler","year":"2013","unstructured":"Weksler B, Romero IA, Couraud P-O (2013) The hCMEC\/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 10:1\u201310. https:\/\/doi.org\/10.1186\/2045-8118-10-16","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"1567_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1021\/mp050088t","volume":"3","author":"Y Xiao","year":"2006","unstructured":"Xiao Y, Davidson R, Smith A, Pereira D, Zhao S, Soglia J, Gebhard D, de Morais S, Duignan DB (2006) A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol Pharm 3(1):45\u201354. https:\/\/doi.org\/10.1021\/mp050088t","journal-title":"Mol Pharm"},{"key":"1567_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118294","volume":"260","author":"T Yu","year":"2020","unstructured":"Yu T, An Q, Cao XL, Yang H, Cui J, Li ZJ, Xiao G (2020) GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K\/AKT\/mTOR pathway. Life Sci 260:118294. https:\/\/doi.org\/10.1016\/j.lfs.2020.118294","journal-title":"Life Sci"},{"issue":"1","key":"1567_CR64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.apsb.2020.05.001","volume":"11","author":"K Yuan","year":"2021","unstructured":"Yuan K, Wang X, Dong H, Min W, Hao H, Yang P (2021) Selective inhibition of CDK4\/6: a safe and effective strategy for developing anticancer drugs. Acta Pharmacol Sin B 11(1):30\u201354. https:\/\/doi.org\/10.1016\/j.apsb.2020.05.001","journal-title":"Acta Pharmacol Sin B"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01567-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-025-01567-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01567-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:58:11Z","timestamp":1762318691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-025-01567-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":64,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1567"],"URL":"https:\/\/doi.org\/10.1007\/s12272-025-01567-9","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}